62906-3

LOINC code 62906-3 identifies "PhenX - personal and family history of psoriasis protocol 170501". The Self Evaluation plus Medication Survey is a self-administered instrument which was developed from the questionnaires used in the Collaborative Association Study of Psoriasis (CASP), which is a Genetic Association Information Network (GAIN) genome-wide association study (GWAS). The Self Evaluation plus Medication Survey collects information on individuals with psoriasis and controls, and their family history of psoriasis and other autoimmune diseases. Additionally, for individuals with psoriasis the questionnaire collects information regarding their symptoms and medication use and its effectiveness. The PhenX Skin, Bone, Muscle and Joint Working Group (WG) recommends that investigators provide participants with an informed consent form which allows future contact for physician validation of their diagnosis and to update information on their health status. Immediately following the alcohol and tobacco questions, the Self Evaluation plus Medication Survey asked questions regarding the respondent's weight and height. These questions have been deleted. The Working Group recommends that this information be obtained via the PhenX measures titled Weight and Height, respectively. These measures are located in the PhenX Toolkit, under the Anthropometrics domain.

This code measures PhenX - personal and family history of psoriasis protocol 170501 in ^Patient. It belongs to the PANEL.PHENX class in the LOINC classification.

LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.